$HELP

So Eric H. L. purchased $1.2M of HELP

So Eric H. L. (Executive Chair) purchased 100,000 shares of CYBIN INC. (HELP) at $12.09 ($1.21M total) on 2026-09-04.

Original reporting
SEC EDGAR · So Eric H. L.
Published Sep 10, 2026, 10:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 10:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
medium confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishMed
01

Why it matters

The insider buy may attract short‑term buying interest, but the effect depends on broader market sentiment toward CYBIN.

02

Market read

Primary insider purchase provides fresh data for traders monitoring micro‑cap biotech stocks.

03

What to watch

Potential upcoming dilution or secondary offerings could offset the positive signal.

Relevance 7/10Novelty 8/10Timing: filing date 2026-09-10

Background

Form 4 filings disclose insider transactions; a $1.2M purchase by the executive chair is a primary source of new information.

Company-level read

Ticker impact

$HELPBullishMedium confidence
Context

Executive Chair So Eric H. L. purchased 100,000 shares of CYBIN Inc. for $1.2M, increasing his stake to over 4.3 million shares.

Expected impact

Possible short-term upside as investors interpret the buy as a bullish signal.

Evidence & confidence

The $1.2M purchase is material for a micro‑cap and represents a sizable increase in insider ownership.

Market effects

None beyond the company.

None.

Limited to investors tracking insider activity.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • CYBIN Inc.

    Biotech firm listed on NASDAQ under ticker HELP.

  • So Eric H. L.

    Executive Chair of CYBIN Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.